To require the Department of Health and Human Services to release documents, communications, and other information relating to most favored nation pricing agreements and other private or confidential drug pricing deals struck with manufacturers, and for other purposes.
Summary
HR9699, introduced by Rep. Chu (D-CA), would force HHS to publicly release confidential drug pricing agreements, including most-favored-nation deals. The bill is in early stage (referred to three committees) with 23 Democratic cosponsors. If enacted, it would increase pricing transparency, pressuring drug manufacturers ($JNJ, $LLY) and PBMs ($UNH) by exposing proprietary discount structures. Near-term market impact is low due to legislative hurdles.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9699 is an early-stage transparency bill with no Republican cosponsors, making passage unlikely in the current Congress.
- 2.If enacted, the bill would expose confidential drug pricing deals, pressuring net prices for manufacturers like $JNJ and $LLY and PBM margins for $UNH.
- 3.No direct market impact expected in the near term; the bill serves as a legislative signal for future drug pricing reform.
Market Implications
The bill's introduction has no immediate market impact given its early stage and partisan sponsorship. However, it adds to the growing legislative pressure on drug pricing transparency. For and $LLY, any future advancement of this bill could create headwinds for their pharmaceutical pricing power. For , the PBM transparency angle could compound existing regulatory scrutiny on pharmacy benefit managers. Investors should watch for committee markups or a companion Senate bill as catalysts.
Full Analysis
On July 15, 2026, Rep. Judy Chu (D-CA) introduced HR9699, a bill requiring the Department of Health and Human Services to disclose documents, communications, and information related to most-favored-nation pricing agreements and other confidential drug pricing deals with manufacturers. The bill has been referred to the Committees on Energy and Commerce, Ways and Means, and the Budget — a typical path for healthcare pricing legislation. With 23 Democratic cosponsors and no Republican support, the bill faces an uphill battle in the Republican-controlled House. It is in the earliest legislative stage; no hearings or markups have occurred.
The money trail: HR9699 does not authorize or appropriate any funding. Its mechanism is purely informational — mandating transparency. The economic impact would come from the downstream effects of exposed pricing data: manufacturers and PBMs would lose negotiating leverage, potentially leading to lower net drug prices in federal programs (Medicare Part D, Medicaid, VA, DoD). This could reduce revenue for drug companies and squeeze PBM margins, but the magnitude depends on how aggressively the disclosed data is used in future negotiations.
Convergence: No related presidential actions or other signals directly connect to this bill. The recent presidential proclamation on chemical manufacturing regulatory relief is unrelated to drug pricing. This bill stands alone as a transparency push.
Structural winners and losers: The primary losers are drug manufacturers with significant federal program exposure and PBMs that negotiate confidential rebates. (pharma segment ~55% of $85.2B revenue) and $LLY (diabetes/obesity drugs ~70% of $34.1B revenue) are most exposed among the provided tickers. $UNH's Optum Rx PBM would face margin pressure. Winners would be taxpayers and government payers, but no public company directly benefits from this bill.
Timeline: The bill is at the referral stage. Given the partisan divide and early stage, passage in the 119th Congress is unlikely. However, the issue of drug pricing transparency has bipartisan appeal in principle, so the bill could serve as a marker for future negotiations. Investors should monitor committee activity and any companion bill in the Senate.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Mandatory disclosure of confidential most-favored-nation pricing agreements and other drug pricing deals between HHS and manufacturers.
Who must act
HHS — must release documents, communications, and information related to drug pricing agreements with manufacturers.
What happens
Exposure of Lilly's pricing and rebate structures for key products (e.g., Mounjaro, Zepbound, Trulicity) in federal programs, reducing pricing opacity and potentially enabling more aggressive government negotiation.
Stock impact
Lilly's revenue is heavily concentrated in diabetes and obesity drugs (over 70% of $34.1B FY2025 revenue). These products face intense competition and rely on confidential rebates for formulary placement. Transparency could compress net prices, especially for high-list-price drugs. A 1-2% net price reduction would impact revenue by $341M-$682M.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
8-K: KIORA PHARMACEUTICALS INC — Officer Departure / Appointment
To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →